All In MedTech

Company

Arthrex

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

From SEC filings.

We found no SEC financing filings under the name Arthrex, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Arthrex.

Latest FDA decisions

Search the Clearance Tracker

No 510(k), De Novo or PMA decisions under this name since 2015.

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT05765266 · 45 participants · Start May 13, 2024 · Primary completion Jul 15, 2025

    Device: ACP Max™; Depo-Medrol® · For: Knee Osteoarthritis

    Sites: Winston-Salem, North Carolina; Knoxville, Tennessee; Danville, Virginia

  • NCT04715139 · 700 participants (planned) · Start Dec 1, 2020 · Primary completion Dec 1, 2027

    Device: Products listed in Group/Cohort Description · For: Hyperpronated Foot; Reconstruction Surgeries of the Foot; Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle and 11 more

    Sites: Sacramento, California; Chicago, Illinois; Nashville, Tennessee · 7 sites in all

  • NCT05046600 · 650 participants (planned) · Start Jul 20, 2021 · Primary completion Dec 1, 2025

    Device: Products listed in cohort description · For: Ulnar/Radial Collateral Ligament Reconstruction; Ligament Repair or Reconstruction; Small Bone Fragments and Arthrodesis and 7 more

    Sites: Phoenix, Arizona; Tuscon, Arizona; Iowa City, Iowa · 5 sites in all

14 more trials with a free account

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor

No reports to chart for this view.

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

No device types to rank.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

No brand names to rank.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls under this name in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.